Judge orders CVS' Omnicare unit to pay $949 million over invalid prescriptions
In a Monday evening order, U.S. District Judge Colleen McMahon in Manhattan imposed a $542-million penalty for filing 3,342,032 false claims between 2010 and 2018.
McMahon also awarded $406.8 million of damages, representing three times the $135.6 million that a jury awarded on April 29.
The tripling was required under the federal False Claims Act, which lets whistleblowers sue on behalf of the federal government and share in recoveries.
CVS plans to appeal the judgment. The Woonsocket, Rhode Island-based drugstore chain and pharmacy benefits manager bought Omnicare in 2015. Omnicare has asked McMahon to throw out the case or grant a new trial.
"This lawsuit centered on a highly technical prescription dispensing recordkeeping issue that was allowed by law in many states," CVS said in a statement on Tuesday. "There was no claim in this case that any patient paid for a medication they shouldn't have or that any patient was harmed."
The lawsuit was filed in 2015 by Uri Bassan, a former Omnicare pharmacist in Albuquerque, New Mexico, and joined by the federal government in 2019.
They said Omnicare improperly billed Medicare, Medicaid, and Tricare, which serves military personnel, for prescriptions for tens of thousands of patients in assisted-living facilities, group homes for people with special needs, and other long-term care facilities.
Omnicare allegedly assigned new prescription numbers without necessary paperwork and pharmacist approvals, after the original prescriptions expired or ran out of refills.
McMahon rejected CVS' argument that a $948.8-million award violated the U.S. Constitution's prohibition against excessive fines under the Eighth Amendment.
"This was a very big fraud on the government, one that lasted over almost a decade, and one that Omnicare was aware of but avoided taking steps to correct," the judge wrote.
McMahon found CVS jointly liable with Omnicare for $164.8 million of the penalties, after jurors found it failed to stop Omnicare from submitting 30% of the false claims after buying that company. CVS itself did not submit any claims.
The case is U.S. ex rel Bassan v. Omnicare Inc, U.S. District Court, Southern District of New York, No. 15-04179.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
2 hours ago
- Telegraph
Forget Ozempic and Mounjaro, this firm is on the edge of a weight-loss breakthrough
Questor is The Telegraph's stock-picking column, helping you decode the markets and offering insights on where to invest. This year, drug companies have been living under a cloud of uncertainty created by the Trump administration. Threats of tough action on drug pricing and tariffs have fuelled nervousness, while recently agreed cuts to Medicaid in the 'big beautiful bill' are also causing concern. But medicine will always be a priority for the sick, and innovations from the pharmaceutical industry are vital for creating healthier societies as populations age. Biotech giant Amgen looks particularly well placed to weather current uncertainties and prosper from the long-term prospects of its industry. A first-class dividend record, which includes increased payouts in each of the last 13 years, is testament to the resilience of the business. Key to this is that unlike many rivals, no one product dominates Amgen's $33.4bn (£24.7bn) of sales. In fact, the company boasts 14 blockbuster drugs with over $1bn sales each. This product diversity means that while its biggest selling treatment – an osteoporosis drug called Prolia that generated $4.4bn revenues last year – is expected to see rapid declines following its loss of patent protection in February, the company's top line is forecast to grow. The drugs Amgen sells cover a number of different areas, including cancer, cardiovascular disease, osteoporosis and rare diseases. Recent trading has been strong, too, with 21 drugs reporting record sales last year and 14 reporting double-digit growth. Amgen is experiencing particularly strong growth from cholesterol drug Repatha, which is forecast to net $2.8bn this year, and osteoporosis treatment Evenity, both of which target underserved patient groups. Sales are also soaring for cancer drug Blincyto. In terms of the problems posed by Trump, Amgen looks well placed. Tariffs should not be a major issue given it mostly manufactures in the US, where it is currently increasing capacity. Having just opened a new facility in Ohio, it plans to plough another $900m into growth in the state and a further $1bn is being spent building in North Carolina. Much of this spending is aimed at increasing production of biosimilars, which are lower cost versions of existing drugs that have lost patent protection. This focus should help position the group to deal with the US government's drug-pricing agenda because biosimilars help lower healthcare costs. Amgen has said Medicaid cuts could have a material adverse impact on some drug sales, however, the cuts passed in the big beautiful bill last week were scaled back in order to get it approved. Reassurance about prospects can also be taken from the number of top fund managers backing the stock – all among the best-performing 3pc globally according to financial publisher Citywire. A total of 14 of these individuals back the shares. The level of smart-money backing has won Amgen a place in Citywire's Global Elite Companies index, which is home to the 76 very best ideas from among the c.6,000 stocks held across the portfolios of the top managers Citywire tracks. For these backers, the potential of Amgen's drug development is a key part of its attraction. Investors have been particularly excited about a long-lasting obesity drug Amgen has begun late-stage phase III trials for, called MariTide. It produces similar levels of weight-loss as Wegovy and Zepbound, which are multibillion-dollar treatments made by Novo Nordisk and Eli Lilly respectively, but MariTide only needs to be injected once a month or less, compared with weekly for the existing drugs. While the potential is exciting, the market reacted negatively to recent news of high levels of nausea during early use. Amgen reckons it can address this by starting patients on lower doses. Better trial news has recently come from cancer treatments, specifically a stomach cancer drug called Bemarituzumab. Amgen is also looking to extend the uses of some of its existing blockbuster medicines. The company put a record $6bn into research and development last year pursuing new opportunities, which represented more than 18pc of sales and a 25pc increase on 2023. While Amgen's margins have nudged down over recent years, it is nevertheless highly profitable. It reported 46.9pc underlying operating margins last year. Meanwhile, solid earnings per share growth is predicted over the next two years of just over 4pc on an annualised basis. That looks an attractive package with the shares priced at 14 times forecast earnings and yielding 3.4pc, especially once the potential for positive surprises from the busy development pipeline is factored in. British buyers of the shares need to fill out the correct paperwork to minimise withholding taxes and check for any extra dealing costs with brokers. Questor says: buy Ticker: NYSE:AMGN
Reuters
7 hours ago
- Reuters
UK agrees deal with Vietnam to remove pharmaceutical trade barriers
LONDON, July 14 (Reuters) - Britain said it would strike an agreement with Vietnam to make it easier for pharmaceutical firms to sell UK-made medicines in the Southeast Asian nation, under a new trade strategy that emphasises quick, industry-specific deals. Britain launched the new strategy last month, promising a nimbler approach compared to the emphasis it placed on full-fledged free trade agreements following its departure from the European Union. Vietnam will hasten the registration of new medicines and vaccines, while recognising approvals from more regulators, including Britain's Medicines and Healthcare products Regulatory Agency, the British government told Reuters in a statement. The deal is expected to be confirmed later on Monday. "The removal of pharmaceutical barriers with one of our closest trading partners in Asia is a boost for the UK pharmaceutical industry and proof our Industrial and Trade Strategies are already delivering," British trade minister Douglas Alexander said. The deal could be worth 250 million pounds ($337 million) to the British pharmaceutical sector over the next five years, the government added. The UK-Vietnamese Joint Economic and Trade Committee will meet in London on Monday and also discuss financial services and renewable energy. Britain has taken a tougher line on some other sectors, however, with steel imports from Vietnam set to be restricted under a new quota regime. Life sciences, including pharmaceuticals, are a priority sector under Britain's new industrial strategy, which was also launched last month. However, that plan has been delayed by a dispute over drug pricing with the British pharmaceutical sector, which says the government needs to value medicines more fairly and adjust the payments they make back to the health service. ($1 = 0.7415 pounds)
Medical News Today
16 hours ago
- Medical News Today
Mediterranean or plant-based diets may reduce constipation risk with age
Chronic constipation happens when a person has difficulty passing stool for at least three months or more. While people can have chronic constipation at any age, it is more common as people get older.A new study has found that following the Mediterranean diet or a plant-based diet may help lower the risk of chronic constipation in middle-aged and older adults. Researchers estimate that about 15% of the world's population lives with chronic constipation, where constipation lasts for three or more months and has a profound impact on a person's daily you can have chronic constipation at any age, it is more common as we get older. Past studies show that between 15%-30% of adults ages 60 and older have chronic constipation.'Chronic constipation is highly prevalent in older adults and significantly impairs quality of life,' Kyle Staller, MD, MPH, gastroenterologist and director of the Gastrointestinal Motility Laboratory at Massachusetts General Hospital, associate professor of medicine at Harvard Medical School, told Medical News Today. 'It also imposes a substantial burden on the healthcare system, with millions of outpatient and emergency department visits and increased medical costs. As aging is one of the largest risk factors for chronic constipation, identifying accessible, preventive strategies … (are) essential to reduce both personal suffering and healthcare utilization.' Staller is the senior author of a new study recently published in the journal Gastroenterology that found following the Mediterranean diet or a plant-based diet may help lower chronic constipation risk in middle- and older-age adults. 5 dietary patterns and their impact on chronic constipationFor this study, researchers analyzed health data for nearly 96,000 adults with an average age of 72.5 from three cohorts — the Nurses' Health Study (NHS), Nurses' Health Study II, and the Health Professional Follow-up Study (HPFS). Chronic constipation was defined as having symptoms for at least 12 weeks in a year. Researchers assessed study participants' adherence to five dietary patterns: Empirical dietary inflammatory pattern (EDIP) (a tool used to measure how inflammatory a person's diet might be)Low-carbohydrate dietMediterranean dietPlant-based dietary index (PDI) (scoring tool used to determine how much of a person's diet is plant-based)Western diet'The study aimed to capture a wide spectrum of real-world eating patterns that might influence gut function,' Staller explained. 'The five dietary patterns were chosen because they represent evidence-based dietary guidelines with known cardiovascular benefits (Mediterranean diet), popular health-conscious choices (plant-based and low-carb diets), typical modern diets (Western diet), and a diet with evidence showing inflammatory potential (inflammatory diet), thus allowing for a comprehensive evaluation of dietary impacts on constipation risk.'— Kyle Staller, MD, MPHMed diet, plant-based diet helps lower chronic constipation riskUpon analysis, Staller and his team found that study participants following the Mediterranean or plant-based diets had a lower risk for developing chronic constipation.'This finding highlights the potential for long-term adherence to diets rich in vegetables, nuts, and healthy fats to lower the risk of chronic constipation, independent of total fiber intake,' Staller said. 'It supports using whole dietary patterns, not just isolated nutrients, as preventive strategies. These diets may work by modulating the gut microbiome, increasing short-chain fatty acid production, and reducing systemic inflammation — all of which contribute to improved gut motility and function,' he researchers discovered that participants who followed the Western or inflammatory diet were more likely to develop chronic diets increase risk of constipation? 'Our data suggest that diets high in processed foods, red meats, and refined grains — common in Western and inflammatory diets — may increase the risk of chronic constipation. Although the mechanism by which these effects occur was not studied, these diets may promote gut inflammation and negatively affect gut microbiota, emphasizing the importance of limiting such dietary patterns for better gastrointestinal health.'— Kyle Staller, MD, MPH'We have hypothesized that the benefits of the Mediterranean diet may be mediated through its impact on the gut microbiome,' Staller continued. 'We would like to examine the microbiome profile among those consuming a Mediterranean diet who do not develop constipation with aging and compare it to those consuming a Western diet who do develop constipation. If these studies support a mechanistic rationale for the Mediterranean diet, we would pilot a feeding study to see if the Mediterranean diet can treat older adults who have already developed chronic constipation,' he added. More constipation as we ageMNT had the opportunity to speak with Ashkan Farhadi, MD, a board certified gastroenterologist at MemorialCare Orange Coast Medical Center in Fountain Valley, CA, and author of The Rhymes of Happiness: Weaving Science, Art and Poetry in the Pursuit of Happiness, about this study, who commented this research helps validate what doctors know what to be right with data to back it up. 'When we get older, most of the movement in the body gets slower, and that does not exclude the colon,' Farhadi explained. 'Many studies have shown as we grow older, the transit time in the colon is reduced in speed and frequencies. And it's not surprising that people get more constipated as they get older.''The other factor that is also important in this equation is [a] busy lifestyle,' he continued. 'One of the most common factors for constipation [i]s when you are busy, basically you ignore the urge, and after a while the colon gets tired sending messages and people get constipated.' 'To counter that, there are a couple of measures — one of them that is very important is diet,' Farhadi added. 'And this study is a strong, important, fact-based piece of information that we can use to help to counter that constipation.' How to encourage 'regular' bowel movementsMNT asked Monique Richard, MS, RDN, LDN, a registered dietitian nutritionist and owner of Nutrition-In-Sight, for her top tips on how readers can keep their bowel movement more 'regular' and help lower their risk for chronic constipation. 'Constipation isn't just about fiber — it's about rhythm, hydration, movement, and microbiome love,' Richard explained. 'Meeting with a registered dietitian nutritionist (RDN) can also explore the variables that could be addressed, including gut bacteria composition and metabolic pathways, as well as nutrient depletion, hydration status, and other physiological interference.'For general tips in reducing constipation, Richard recommends: Incorporating a variety of three to five servings of whole grains daily, such as oats, amaranth, quinoa, millet, rice, buckwheat, and four to six servings daily of varying fruits and vegetables based on what's local and in season. Hydrate throughout the day with water, herbal, or black and green healthy fats when cooking, as snacks, or as toppers to a meal, such as olive oil to a saute, nuts, or nut butters with fruit for a snack, or topping a salad with sesame seeds or toasted walnutsNourish the gut microbiota with foods rich in polyphenols such as berries, cocoa powder, and herbs and spices such as oregano, peppermint, sage, clove, and rosemary. The intestinal tract thrives with fresh oxygen flow and blood exchange — go for a walk, practice yoga, or participate in movement that you enjoy and can participate in on a regular basis, to help keep you magnesium intake is associated with constipation, especially in older adults. Incorporate foods rich in magnesium, such as pumpkin seeds, almonds, dark leafy greens, avocado, and and kiwi can be a delightful way to prevent constipation — add a couple for a snack with some nuts or seeds. Make a meal with beans a few times a week; add lentils to sides and main meals; snack on roasted garbanzo beans or consistent with meal time — bodies thrive on a schedule that lets them rest and digest with plenty of time in between to clean up and disseminate nutrients. Try to keep mealtime around the same times every day for breakfast, lunch, and dinner, and plenty of time for rest between dinner and bedtime.'Real food, regular meals, and rest are non-negotiables in supporting gut health and effective elimination,' Richard added. 'The quality of input affects the output and everything in between.'
